A detailed history of Pnc Financial Services Group, Inc. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 2,520 shares of CRNX stock, worth $137,894. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,520
Previous 197 1179.19%
Holding current value
$137,894
Previous $8,000 1500.0%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$43.83 - $54.98 $101,817 - $127,718
2,323 Added 1179.19%
2,520 $128,000
Q2 2024

Aug 09, 2024

BUY
$42.12 - $51.91 $3,369 - $4,152
80 Added 68.38%
197 $8,000
Q1 2024

May 10, 2024

BUY
$34.76 - $46.81 $3,858 - $5,195
111 Added 1850.0%
117 $5,000
Q4 2023

Feb 09, 2024

BUY
$25.62 - $37.07 $153 - $222
6 New
6 $0

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.94B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Pnc Financial Services Group, Inc. Portfolio

Follow Pnc Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.